Bausch Health Companies Inc. Effective Income Tax Rate Reconciliation, Tax Settlement, Amount
Bausch Health Companies Inc. (BHC) reported Effective Income Tax Rate Reconciliation, Tax Settlement, Amount of -$36.00 million for the 6-month period ending 2025-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxSettlements · last filed 2026-07-30
- Bausch Health Companies Inc. effective income tax rate reconciliation, tax settlement, amount for the quarter ending 2023-09-30 was $0.00.
- Bausch Health Companies Inc. effective income tax rate reconciliation, tax settlement, amount for the quarter ending 2023-06-30 was $0.00.
- Bausch Health Companies Inc. effective income tax rate reconciliation, tax settlement, amount for the quarter ending 2023-03-31 was $41.00M.
| Period end | Effective Income Tax Rate Reconciliation, Tax Settlement, Amount 3 month | Effective Income Tax Rate Reconciliation, Tax Settlement, Amount 6 month | Effective Income Tax Rate Reconciliation, Tax Settlement, Amount 9 month |
|---|---|---|---|
| 2025-06-30 | -$36.00M 10-Q · filed 2026-07-30 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $0.00 derived: sum of 2 quarters · filed 2024-10-31 | $41.00M 10-Q · filed 2024-10-31 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $41.00M 10-Q · filed 2024-08-01 | |
| 2023-03-31 | $41.00M 10-Q · filed 2024-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |